LifeStance Health Group Past Earnings Performance
Past criteria checks 0/6
LifeStance Health Group has been growing earnings at an average annual rate of 7.4%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 29.4% per year.
Key information
7.4%
Earnings growth rate
188.3%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 29.4% |
| Return on equity | -13.0% |
| Net Margin | -17.6% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Calculating The Intrinsic Value Of LifeStance Health Group, Inc. (NASDAQ:LFST)
Mar 23
LifeStance Health Group, Inc. (NASDAQ:LFST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50
Mar 02LifeStance Q4 Earnings Review: Monetizing Mental Health Virtually Is Problematic
Feb 29Does LifeStance Health Group (NASDAQ:LFST) Have A Healthy Balance Sheet?
Feb 28LifeStance Health Group, Inc.'s (NASDAQ:LFST) P/S Still Appears To Be Reasonable
Jan 23What Is LifeStance Health Group, Inc.'s (NASDAQ:LFST) Share Price Doing?
Jul 08Is LifeStance Health Group, Inc. (NASDAQ:LFST) Expensive For A Reason? A Look At Its Intrinsic Value
May 09LifeStance Health appoints new key person
Sep 08Is LifeStance Health Group, Inc. (NASDAQ:LFST) Trading At A 48% Discount?
Sep 05LifeStance Health Reiterates Guidance Amid High Operating Losses
Jul 19Health Care falls 2.8% in June, Nutex, CureVac biggest losers
Jul 01An Intrinsic Calculation For LifeStance Health Group, Inc. (NASDAQ:LFST) Suggests It's 47% Undervalued
May 26LifeStance Health Group: Real Issues
Apr 28Revenue & Expenses BreakdownBeta
How LifeStance Health Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,056 | -186 | 399 | 0 |
| 30 Sep 23 | 1,004 | -188 | 349 | 0 |
| 30 Jun 23 | 959 | -164 | 356 | 0 |
| 31 Mar 23 | 909 | -187 | 357 | 0 |
| 31 Dec 22 | 860 | -216 | 376 | 0 |
| 30 Sep 22 | 820 | -277 | 414 | 0 |
| 30 Jun 22 | 776 | -360 | 504 | 0 |
| 31 Mar 22 | 727 | -361 | 495 | 0 |
| 31 Dec 21 | 668 | -344 | 431 | 0 |
| 30 Sep 21 | 596 | -515 | 331 | 0 |
| 30 Jun 21 | 524 | -397 | 185 | 0 |
| 31 Mar 21 | 447 | -331 | 113 | 0 |
| 31 Dec 20 | 377 | -286 | 88 | 0 |
| 31 Dec 19 | 213 | -59 | 48 | 0 |
Quality Earnings: LFST is currently unprofitable.
Growing Profit Margin: LFST is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LFST is unprofitable, but has reduced losses over the past 5 years at a rate of 7.4% per year.
Accelerating Growth: Unable to compare LFST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LFST is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.3%).
Return on Equity
High ROE: LFST has a negative Return on Equity (-13.04%), as it is currently unprofitable.